LEAP Therapeutics, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • LPTX (NCM)

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

617 714 0360 47 Thorndike Street, Cambridge, MA 02141, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PR Newswire

PR Newswire • Oct 6

Leap Therapeutics Stock More Than Doubles On Zcash Treasury Pivot – Former POTUS Advisor Calls It ‘Gangster’ Move - Stocktwits

Stocktwits • Nov 12

Leap Therapeutics stock soars after securing $58.9M investment By Investing.com - Investing.com

Investing.com • Oct 6

Leap Therapeutics Surges 300% on $50M Winklevoss-Backed Zcash Bet - Yahoo! Finance Canada

Yahoo! Finance Canada • Nov 12

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data - FinancialContent

FinancialContent • Oct 3

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has LEAP THERAPEUTICS, INC. had layoffs?

No layoff events have been recorded for LEAP THERAPEUTICS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does LEAP THERAPEUTICS, INC. have?

LEAP THERAPEUTICS, INC. has approximately 52 employees.

What industry is LEAP THERAPEUTICS, INC. in?

LEAP THERAPEUTICS, INC. operates in the Biotechnology industry, within the Healthcare sector.

Is LEAP THERAPEUTICS, INC. a publicly traded company?

Yes, LEAP THERAPEUTICS, INC. is publicly traded under the ticker symbol LPTX on the NCM. The company has a market capitalization of approximately $0.12 billion.

Where is LEAP THERAPEUTICS, INC. headquartered?

LEAP THERAPEUTICS, INC. is headquartered in Cambridge, MA, United States at 47 Thorndike Street, Cambridge, MA 02141, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.